Overview
Recurrent primary malignant neoplasms of the vulva represent a significant clinical challenge, often arising despite initial comprehensive treatment modalities such as surgery, radiation, and chemotherapy. These recurrences can manifest in various forms, including isolated lesions, involvement of critical structures, and groin metastases, each necessitating tailored therapeutic approaches. The management of recurrent vulvar cancer requires a multidisciplinary approach, integrating surgical techniques, radiation therapy, and novel modalities like electrochemotherapy (ECT). Understanding the epidemiology, clinical presentation, and evolving treatment strategies is crucial for optimizing patient outcomes and quality of life.
Epidemiology
Vulvar cancer has a relatively low incidence, ranging from 1 to 2 cases per 100,000 individuals annually. However, recurrence is a notable concern, affecting approximately one-third of patients, typically within the first two years following primary treatment [PMID:12965138]. This high recurrence rate underscores the aggressive nature of vulvar malignancies and the importance of vigilant follow-up care. The demographic profile of patients with recurrent disease often includes older adults, with studies indicating a mean age of around 76 years, and a significant proportion having undergone prior surgical and/or radio-chemotherapy interventions [PMID:26882959]. These factors highlight the complexity of managing recurrent disease in a population that may have compromised healing capacities and multiple comorbidities.
Clinical Presentation
The clinical presentation of recurrent vulvar cancer is diverse, with squamous cell carcinoma being the predominant histological subtype, accounting for 14 out of 15 cases in one study [PMID:32371425]. A notable pattern observed is the frequent occurrence of multiple lesions, affecting 66.7% of patients, which complicates both diagnosis and treatment planning. These multifocal recurrences can arise from residual disease or new primary sites, necessitating thorough physical examinations and imaging studies to delineate the extent of disease involvement. Additionally, the clinical scenario often includes patients with a history of previous interventions, emphasizing the need for comprehensive reassessment to tailor subsequent management strategies effectively.
Diagnosis
Diagnosing recurrent vulvar cancer involves a combination of clinical evaluation, imaging techniques, and histopathological confirmation. Physical examination remains foundational, often supplemented by imaging modalities such as MRI or CT scans to assess the extent of local recurrence and potential involvement of adjacent structures like the urethra, bladder, vagina, and anorectal canal [PMID:12965138]. Biopsy confirmation is essential for accurate staging and to rule out new primary malignancies. Given the complexity and variability in recurrence patterns, multidisciplinary input from gynecologic oncologists, radiologists, and pathologists is crucial for precise diagnosis and staging, guiding appropriate treatment decisions.
Management
Surgical Approaches
For isolated vulval recurrences, which account for up to 50% of cases, radical wide local excision remains a cornerstone of curative intent treatment [PMID:12965138]. This approach aims to achieve clear margins while minimizing functional and cosmetic morbidity. However, larger defects often necessitate reconstructive techniques, such as the use of skin flaps, to ensure proper wound closure and functional outcomes. Subcutaneously pedicled or perforator-based gluteal fold flaps have shown promising results in managing recurrent vulvoperineal malignancies, with complete flap survival and healing reported in 9 women, despite some short-term complications [PMID:29664826]. These reconstructive strategies are particularly valuable in preserving quality of life and functional integrity.
Advanced Recurrences and Critical Structures
Recurrences involving critical structures such as the urethra, bladder, vagina, and anorectal canal pose significant therapeutic challenges. In these scenarios, radical exenterative procedures are often recommended to achieve complete resection and potentially curative outcomes [PMID:12965138]. These extensive surgeries aim to remove all visible disease while preserving organ function to the greatest extent possible. However, they carry substantial morbidity and require careful patient selection and multidisciplinary planning.
Groin Recurrences
Groin recurrences are particularly challenging, often leading to unsuccessful surgical debulking efforts due to the diffuse nature of disease spread [PMID:12965138]. In such cases, chemoradiation therapy emerges as a pivotal strategy, combining systemic cytotoxic agents with targeted radiation to control disease progression and alleviate symptoms. This multimodal approach aims to achieve local control and extend survival, especially when surgical options are limited.
Electrochemotherapy (ECT)
Electrochemotherapy, utilizing intravenous bleomycin administration coupled with electrical pulses, has emerged as a promising palliative treatment modality for recurrent vulvar cancer [PMID:26882959], [PMID:32371425]. Studies involving multiple patients have demonstrated an 80% response rate at one month, highlighting its feasibility and tolerability [PMID:32371425]. ECT not only achieves local control but also provides symptomatic relief, making it particularly valuable in elderly patients or those with advanced disease who may not be candidates for more aggressive treatments [PMID:26882959]. The evidence suggests that ECT can significantly improve quality of life and local disease control, positioning it as a viable option in the palliative care armamentarium.
Complications
While electrochemotherapy and reconstructive surgeries offer promising outcomes, they are not without risks. Post-ECT procedures have generally been well-tolerated, with no intra-procedure complications reported in some studies [PMID:32371425]. However, vigilant monitoring post-procedure is essential, as evidenced by one patient developing pneumonia, underscoring the importance of close clinical observation and supportive care [PMID:32371425]. Similarly, although flap reconstructions demonstrate high success rates with complete healing observed in most cases [PMID:29664826], short-term complications such as wound dehiscence or infection were noted in a subset of patients (3 out of 9), necessitating meticulous postoperative care and monitoring [PMID:29664826].
Prognosis & Follow-up
The prognosis for patients with recurrent vulvar cancer varies significantly based on the extent and location of recurrence. Disease recurrence in the groin portends a particularly poor prognosis, with limited survival rates, emphasizing the critical need for early integration of palliative care measures [PMID:12965138]. Follow-up studies indicate that while outcomes can be guarded, there are encouraging signs of prolonged survival and symptom relief. For instance, at one-year follow-up, 50% of patients treated with ECT remained alive, suggesting potential palliative benefits [PMID:32371425]. Similarly, patients undergoing flap reconstructions showed sustained healing and functional outcomes over a mean follow-up period of 27 months [PMID:29664826]. Regular follow-up, including clinical assessments and imaging, is crucial for early detection of new recurrences and timely intervention, thereby optimizing patient outcomes.
Special Populations
Elderly patients and those with a history of extensive prior treatments represent a significant subgroup affected by recurrent vulvar cancer. These individuals often face unique challenges due to age-related comorbidities and potential treatment limitations. Electrochemotherapy (ECT) has demonstrated efficacy in this vulnerable population, improving local control and quality of life without imposing the high burden associated with conventional aggressive therapies [PMID:26882959]. Tailoring treatment approaches to consider the overall health status and functional capacity of these patients is essential for achieving optimal outcomes while maintaining their quality of life.
Key Recommendations
References
1 Corrado G, Cutillo G, Fragomeni SM, Bruno V, Tagliaferri L, Mancini E et al.. Palliative electrochemotherapy in primary or recurrent vulvar cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020. link 2 Hage JJ, Lange M, Zijlmans HJ, van Beurden M. Repeated Use of Gluteal Fold Flaps for Post-Oncologic Vulvoperineal Reconstruction. Annals of plastic surgery 2018. link 3 Pellegrino A, Damiani GR, Mangioni C, Strippoli D, Loverro G, Cappello A et al.. Outcomes of Bleomycin-based electrochemotherapy in patients with repeated loco-regional recurrences of vulvar cancer. Acta oncologica (Stockholm, Sweden) 2016. link 4 Coulter J, Gleeson N. Local and regional recurrence of vulval cancer: management dilemmas. Best practice & research. Clinical obstetrics & gynaecology 2003. link00050-6)